Autolus Therapeutics plc (FRA:6A3A)
Germany · Delayed Price · Currency is EUR 1.360
-0.040 (-2.86%)
At close: Jun 26, 2026
Autolus Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 92.62 | 75.39 | 10.01 | 1.7 | 6.38 | 1.51 | |
Revenue Growth (YoY) | 927.90% | 652.77% | 489.79% | -73.38% | 323.23% | 522.73% |
Cost of Revenue | 102.99 | 96.37 | 13.91 | - | - | - |
Gross Profit | -10.36 | -20.98 | -3.9 | 1.7 | 6.38 | 1.51 |
Selling, General & Admin | 142.29 | 131.87 | 99.44 | 46.75 | 34.13 | 31.87 |
Research & Development | 112.17 | 117.69 | 141.82 | 130.48 | 136.23 | 110.84 |
Other Operating Expenses | - | - | 0.39 | 4.17 | 1.51 | 0.68 |
Operating Income | -264.82 | -270.54 | -245.54 | -179.7 | -165.49 | -141.87 |
Interest Income | 15.31 | 18.98 | 41.44 | 13.51 | 10.53 | 0.26 |
Interest Expense | -37.65 | -36.67 | -13.96 | -45.07 | -10.39 | -1.11 |
Other Non-Operating Income (Expense) | -1.2 | 2.68 | - | 2.86 | - | -0.15 |
Total Non-Operating Income (Expense) | -23.54 | -15.01 | 27.48 | -28.7 | 0.14 | -0.99 |
Pretax Income | -288.36 | -285.56 | -218.06 | -208.4 | -165.35 | -142.04 |
Provision for Income Taxes | -1.79 | -1.97 | 15.99 | 0.02 | 23.37 | -0.06 |
Net Income | -286.56 | -283.58 | -234.05 | -208.42 | -188.72 | -141.98 |
Net Income to Common | -288.97 | -287.53 | -202.07 | -208.38 | -141.98 | -142.1 |
Shares Outstanding (Basic) | 266 | 266 | 255 | 174 | 95 | 72 |
Shares Outstanding (Diluted) | 266 | 266 | 255 | 174 | 95 | 72 |
Shares Change (YoY) | 0.02% | 4.30% | 46.69% | 83.11% | 31.78% | 39.81% |
EPS (Basic) | -1.09 | -1.13 | -0.79 | -1.20 | -1.50 | -1.97 |
EPS (Diluted) | -1.09 | -1.13 | -0.79 | -1.20 | -1.50 | -1.97 |
Free Cash Flow | -220.37 | -143.31 | -610.31 | -156.57 | -114.57 | -126.72 |
Free Cash Flow Per Share | -0.83 | -0.54 | -2.39 | -0.90 | -1.21 | -1.76 |
Gross Margin | -11.19% | -27.83% | -38.93% | 100.00% | 100.00% | 100.00% |
Operating Margin | -285.90% | -358.87% | -2451.82% | -10583.10% | -2594.67% | -9414.27% |
Profit Margin | -309.38% | -376.17% | -2337.06% | -12274.50% | -2958.92% | -9421.37% |
FCF Margin | -237.92% | -190.09% | -6094.14% | -9221.02% | -1796.30% | -8408.63% |
EBITDA | -264.82 | -260.11 | -237.87 | -173.14 | -158.25 | -133.42 |
EBITDA Margin | -285.90% | -345.02% | -2375.23% | -10196.50% | -2481.18% | -8853.02% |
EBIT | -264.82 | -270.54 | -245.54 | -179.7 | -165.49 | -141.87 |
EBIT Margin | -285.90% | -358.87% | -2451.82% | -10583.10% | -2594.67% | -9414.27% |
Effective Tax Rate | 0.62% | 0.69% | -7.33% | -0.01% | -14.13% | 0.04% |